AveXis (NASDAQ:AVXS) and CytRx (NASDAQ:CYTR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Institutional and Insider Ownership
84.1% of AveXis shares are held by institutional investors. Comparatively, 10.0% of CytRx shares are held by institutional investors. 18.6% of AveXis shares are held by insiders. Comparatively, 6.6% of CytRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings for AveXis and CytRx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AveXis currently has a consensus target price of $136.07, indicating a potential downside of 37.53%. CytRx has a consensus target price of $5.00, indicating a potential upside of 426.32%. Given CytRx’s stronger consensus rating and higher possible upside, analysts clearly believe CytRx is more favorable than AveXis.
Earnings and Valuation
This table compares AveXis and CytRx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
CytRx has higher revenue and earnings than AveXis. AveXis is trading at a lower price-to-earnings ratio than CytRx, indicating that it is currently the more affordable of the two stocks.
This table compares AveXis and CytRx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
AveXis has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, CytRx has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500.
CytRx beats AveXis on 8 of the 12 factors compared between the two stocks.
AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.